LifeNet Health launches the Vertigraft Cervical Bio-Implant with Preservon Technology

LifeNet Health, a leading allograft bio-implant company, announces the launch of Vertigraft Cervical Bio-Implant (VG2C) with Preservon® Technology

Preservon® is a new, proprietary glycerol-based preservation solution that allows allograft bio-implants to be stored in a fully hydrated state at ambient temperature. This eliminates the need to freeze or freeze-dry bio-implants, doing away with lengthy thawing and rehydration times in operating rooms. VG2C with Preservon® represents the first machined composite bio-implant allografts delivered to the operating room in a fully hydrated state without the need for frozen storage.

VG2C allograft bio-implants in frozen form have been one of the most widely utilized machined allografts for anterior cervical fusion surgery, with over 200,000 grafts distributed since 2002. This new ambient storage packaging provides greater convenience for the hospital and OR staff and eliminates the need for expensive freezer storage while retaining the proven performance that surgeons have grown to trust for their patients.

Preservon® combined with LifeNet Health's patented Allowash XG process delivers a sterile (SAL of 10(-6)) allograft bio-implant with the full mechanical properties associated with frozen grafts in an ambient storage package.

"This is a leading advancement in our field. Preservon® allograft bio-implants will save valuable OR time and preserve product integrity. It will benefit surgeons, hospitals and most importantly the patients whom we serve. This is part of our mission in saving lives and restoring health," said Rony Thomas, LifeNet Health CEO and President.

Preservon® is one of several process technology platforms that LifeNet Health has developed to enhance the utility and clinical effectiveness of human allograft tissue. LifeNet Health is currently evaluating other applications that can benefit from this break-through technology including skin, cartilage and other cardiovascular tissues.

Since 1995, LifeNet Health has distributed more than two million bio-implants with no incidence of disease transmission linked to tissue screened and processed using LifeNet Health's proprietary Allowash XG® technology. All allograft tissue undergoes a multi-step quality assurance review that exceeds the standards set by both the FDA and American Association of Tissue Banks (AATB).